Previous 10 | Next 10 |
New data from the RESPOND study show that neurofilament levels, an indicator of neurodegeneration, were reduced in nearly all study participants treated with SPINRAZA Reductions in biomarker complement previously reported RESPOND efficacy results showing improved motor function in most part...
Ionis announces new chief global product strategy officer to lead next phase of commercial growth PR Newswire Kyle Jenne rejoins company to lead commercial strategy Onaiza Cadoret-Manier departing for new career opportunity With broad commercial cap...
2024-02-23 17:58:23 ET Summary Ionis Pharmaceuticals, Inc. reported Q4 2023 earnings this week - revenues increased 34% year-on-year to $788m, comfortably outperforming management's guidance. The stock price of Ionis has dipped in 2024 after a lengthy bull run - current market cap...
2024-02-23 07:59:52 ET More on Biogen Biogen's Q4 Earnings Disappoint Amidst Strategic Challenges (Rating Downgrade) Biogen Inc. (BIIB) Q4 2023 Earnings Call Transcript Biogen Inc. 2023 Q4 - Results - Earnings Call Presentation DOJ issues subpoena for info on...
2024-02-21 16:47:06 ET Ionis Pharmaceuticals, Inc. (IONS) Q4 2023 Earnings Conference Call February 21, 2024 11:30 ET Company Participants Wade Walke - Senior Vice President, Investor Relations Brett Monia - Chief Executive Officer Richard Geary - Chief Developme...
2024-02-21 08:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-02-21 07:02:38 ET More on Ionis Pharmaceuticals Ionis Pharmaceuticals: Pioneering Precision Medicine Ionis Pharmaceuticals FY 2023 Earnings Preview Ionis receives FDA orphan drug status for familial chylomicronemia drug Seeking Alpha’s Quant Ratin...
Ionis reports fourth quarter and full year 2023 financial results PR Newswire WAINUA™ approved with launch underway; on track for EU and Canada approval decisions this year Positive Phase 3 olezarsen and donidalorsen data, preparing regulatory submission...
Vimeo Inc. (VMEO) is expected to report $-0.01 for Q4 2023 Heineken N.V ADR (HEINY) is expected to report for Q4 2023 American States Water Company (AWR) is expected to report $0.53 for Q4 2023 NextPlay Technologies Inc. (NXTP) is expected to report for Q3 2024 Inseego Corp. (INSG...
2024-02-20 21:29:31 ET Summary Tweedy Browne's 13F portfolio value increased from $1.87B to $2.05B this quarter. The largest position in the portfolio is Berkshire Hathaway at ~21%. Stake increases include FMC Corporation, U-Haul Holding, and Sealed Air, while stake decreases ...
News, Short Squeeze, Breakout and More Instantly...
Ionis Pharmaceuticals Inc. Company Name:
IONS Stock Symbol:
NASDAQ Market:
Ionis Pharmaceuticals Inc. Website:
Ionis to hold first quarter 2024 financial results webcast PR Newswire Webcast scheduled for Tuesday, May 7 at 11:30 a.m. Eastern Time CARLSBAD, Calif. , April 23, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced toda...
2024-04-12 13:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-04-09 18:30:03 ET Wolfe Research analyst issues OUTPERFORM recommendation for IONS on April 9, 2024 04:39PM ET. IONS was trading at $42.83 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 6 - Buy, 3 -...